Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats.

Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, Buljan M, Vranes H, Giljanovic A, Drmic D, Japjec M, Prtoric A, Lovric E and 6 more

Show all authors

Batelja Vuletic L, Dobric I, Boban Blagaic A, Skrtic A, Seiwerth S, Predrag S

Biomedicines27 Oct 2021Cited by 20 (Europe PMC)

PMID34829776PMCIDPMC8615275DOI10.3390/biomedicines9111547PepBankPUB-34829776

Download PDF PubMedAsk about this study

Jump to 7 results

Summary

(1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions. BPC 157 (10 µg/kg, 10 ng/kg) regimen was given (i) intraperitoneally, first application immediately after surgery, last 24 h before sacrifice; (ii) per-orally, in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat/day), till the sacrifice at 7, 14, 28 and 42 postoperative days. (3) Results: These BPC 157 regimens document prominent therapy effects (macro/microscopic, biomechanical, functional much like eNOS and COX-2 mRNA levels and counteracted oxidative stress and NO-levels in the myotendinous junctions), while controls have a poor presentation. Especially, in rats with the disabled myotendinous junction, along with full functional recovery, BPC 157 counteracts muscle atrophy that is regularly progressive and brings muscle presentation close to normal. Accordingly, unlike the perilous course in controls, those rats, when receiving BPC 157 therapy, exhibit a smaller defect, and finally defects completely disappear. Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days. (4) Conclusions: BPC 157 restores myotendinous junction in accordance with the healing of the transected muscle, tendon, and ligament.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with a myotendinous junction defect, BPC‑157 regimens improved macroscopic, microscopic, biomechanical and functional outcomes, while controls had a poor presentation.
In plain wordsIn rats with a muscle-tendon junction injury, BPC‑157 improved healing compared with untreated controls.
Peptide
BPC-157
Outcome
IncreaseMacroscopic, microscopic, biomechanical and functional healing of the myotendinous junction
Study
ratn: not reported in source
Quadriceps tendon dissected from the muscle (myotendinous junction defect)
Comparator
Untreated controls
Outcome group
Tendon and ligament healing · Musculoskeletal
Studied dose
10 µg/kg, 10 ng/kg; drinking water 0.16 µg/mL, 0.16 ng/mL · intraperitoneal, or per-oral in drinking water · until sacrifice at 7, 14, 28 and 42 postoperative daysAs given in this study (rat).
Source sentences
Summary
These BPC 157 regimens document prominent therapy effects (macro/microscopic, biomechanical, functional
3 context sentences(design, population, supporting numbers)
Summary · context
while controls have a poor presentation.
Summary · context
Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats.
Summary · context
(2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions.
Show in the study text Report a problemFND-3482977601
02AnimalAnimal study (in vivo)Mechanism
In rats with a myotendinous junction defect, BPC‑157 regimens had therapy effects on eNOS and COX-2 mRNA levels in the junction; the direction is not stated.
In plain wordsIn rats with a muscle-tendon junction injury, BPC‑157 changed two gene activity markers, eNOS and COX-2; the abstract does not give the direction.
Peptide
BPC-157
Outcome
Direction not reportedeNOS and COX-2 mRNA levels
Study
ratn: not reported in source
Quadriceps tendon dissected from the muscle (myotendinous junction defect)
Comparator
Untreated controls
Outcome group
Inflammation markers · Musculoskeletal
Studied dose
10 µg/kg, 10 ng/kg; drinking water 0.16 µg/mL, 0.16 ng/mL · intraperitoneal, or per-oral in drinking water · until sacrifice at 7, 14, 28 and 42 postoperative daysAs given in this study (rat).
Source sentences
Summary
much like eNOS and COX-2 mRNA levels
2 context sentences(design, population, supporting numbers)
Summary · context
Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats.
Summary · context
(2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions.
Show in the study text Report a problemFND-3482977602
03AnimalAnimal study (in vivo)Mechanism
In rats with a myotendinous junction defect, BPC‑157 regimens counteracted oxidative stress in the junctions.
In plain wordsIn rats with a muscle-tendon junction injury, BPC‑157 counteracted oxidative stress in the injured tissue.
Peptide
BPC-157
Outcome
DecreaseOxidative stress in the myotendinous junction
Study
ratn: not reported in source
Quadriceps tendon dissected from the muscle (myotendinous junction defect)
Comparator
Untreated controls
Outcome group
Inflammation markers · Musculoskeletal
Studied dose
10 µg/kg, 10 ng/kg; drinking water 0.16 µg/mL, 0.16 ng/mL · intraperitoneal, or per-oral in drinking water · until sacrifice at 7, 14, 28 and 42 postoperative daysAs given in this study (rat).
Source sentences
Summary
counteracted oxidative stress and NO-levels in the myotendinous junctions), while controls have a poor presentation.
2 context sentences(design, population, supporting numbers)
Summary · context
Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats.
Summary · context
(2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions.
Show in the study text Report a problemFND-3482977603
04AnimalAnimal study (in vivo)Mechanism
In rats with a myotendinous junction defect, BPC‑157 regimens counteracted NO-levels in the junctions; the direction of change is not stated.
In plain wordsIn rats with a muscle-tendon junction injury, BPC‑157 counteracted nitric oxide levels in the injured tissue.
Peptide
BPC-157
Outcome
Direction not reportedNitric oxide levels in the myotendinous junction
Study
ratn: not reported in source
Quadriceps tendon dissected from the muscle (myotendinous junction defect)
Comparator
Untreated controls
Outcome group
Inflammation markers · Musculoskeletal
Studied dose
10 µg/kg, 10 ng/kg; drinking water 0.16 µg/mL, 0.16 ng/mL · intraperitoneal, or per-oral in drinking water · until sacrifice at 7, 14, 28 and 42 postoperative daysAs given in this study (rat).
Source sentences
Summary
counteracted oxidative stress and NO-levels in the myotendinous junctions), while controls have a poor presentation.
2 context sentences(design, population, supporting numbers)
Summary · context
Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats.
Summary · context
(2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions.
Show in the study text Report a problemFND-3482977604
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with a disabled myotendinous junction, BPC‑157 gave full functional recovery and counteracted progressive muscle atrophy, bringing muscle presentation close to normal.
In plain wordsIn rats with a muscle-tendon junction injury, BPC‑157 counteracted muscle wasting and restored function compared with controls.
Peptide
BPC-157
Outcome
DecreaseMuscle atrophy and functional recovery
Study
ratn: not reported in source
Quadriceps tendon dissected from the muscle (myotendinous junction defect)
Comparator
Untreated controls
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
10 µg/kg, 10 ng/kg; drinking water 0.16 µg/mL, 0.16 ng/mL · intraperitoneal, or per-oral in drinking water · until sacrifice at 7, 14, 28 and 42 postoperative daysAs given in this study (rat).
Source sentences
Summary
Especially, in rats with the disabled myotendinous junction, along with full functional recovery, BPC 157 counteracts muscle atrophy that is regularly progressive and brings muscle presentation close to normal.
2 context sentences(design, population, supporting numbers)
Summary · context
Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats.
Summary · context
(2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions.
Show in the study text Report a problemFND-3482977605
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with a myotendinous junction defect, BPC‑157 gave a smaller defect than in controls, and defects finally disappeared.
In plain wordsIn rats, BPC‑157 treated injuries were smaller than in controls and finally closed completely.
Peptide
BPC-157
Outcome
DecreaseSize of the myotendinous junction defect
Study
ratn: not reported in source
Quadriceps tendon dissected from the muscle (myotendinous junction defect)
Comparator
Untreated controls
Outcome group
Tendon and ligament healing · Musculoskeletal
Studied dose
10 µg/kg, 10 ng/kg; drinking water 0.16 µg/mL, 0.16 ng/mL · intraperitoneal, or per-oral in drinking water · until sacrifice at 7, 14, 28 and 42 postoperative daysAs given in this study (rat).
Source sentences
Summary
Accordingly, unlike the perilous course in controls, those rats, when receiving BPC 157 therapy, exhibit a smaller defect, and finally defects completely disappear.
2 context sentences(design, population, supporting numbers)
Summary · context
Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats.
Summary · context
(2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions.
Show in the study text Report a problemFND-3482977606
07AnimalAnimal study (in vivo)Efficacy outcome
In rats with a myotendinous junction defect, BPC‑157 treated rats had no more inflammatory infiltrate and well-oriented recovered tissue at 28 and 42 days.
In plain wordsIn rats, treated injuries showed no more inflammation cells and well-organised tissue after 28 and 42 days.
Peptide
BPC-157
Outcome
DecreaseInflammatory infiltrate at day 28 and day 42
Study
ratn: not reported in source
Quadriceps tendon dissected from the muscle (myotendinous junction defect)
Comparator
Untreated controls
Outcome group
Inflammation markers · Musculoskeletal
Studied dose
10 µg/kg, 10 ng/kg; drinking water 0.16 µg/mL, 0.16 ng/mL · intraperitoneal, or per-oral in drinking water · until sacrifice at 7, 14, 28 and 42 postoperative daysAs given in this study (rat).
Source sentences
Summary
Microscopically, there are no more inflammatory infiltrate, well-oriented recovered tissue of musculotendon junction appears in BPC 157 treated rats at the 28 days and 42 days.
2 context sentences(design, population, supporting numbers)
Summary · context
Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats.
Summary · context
(2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments, eNOS, and COX-2 mRNA levels and oxidative stress and NO-levels in the myotendinous junctions.
Show in the study text Report a problemFND-3482977607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats.

Summary

Results from this study7

Version history

Subjects

Publication types

Keywords